ENALAPRIL\HYDROCHLOROTHIAZIDE: 616 Adverse Event Reports & Safety Profile
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
616
Total FAERS Reports
28 (4.5%)
Deaths Reported
385
Hospitalizations
616
As Primary/Secondary Suspect
34
Life-Threatening
8
Disabilities
Active Ingredient: ENALAPRIL MALEATE\HYDROCHLOROTHIAZIDE ·
First Report: 20030725 · Latest Report: 20250613
What Are the Most Common ENALAPRIL\HYDROCHLOROTHIAZIDE Side Effects?
#1 Most Reported
Acute kidney injury
88 reports (14.3%)
#2 Most Reported
Hyponatraemia
81 reports (13.1%)
#3 Most Reported
Dizziness
55 reports (8.9%)
All ENALAPRIL\HYDROCHLOROTHIAZIDE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Acute kidney injury | 88 | 14.3% | 9 | 86 |
| Hyponatraemia | 81 | 13.2% | 6 | 68 |
| Dizziness | 55 | 8.9% | 0 | 20 |
| Fall | 54 | 8.8% | 1 | 23 |
| Drug interaction | 53 | 8.6% | 1 | 40 |
| Headache | 50 | 8.1% | 0 | 9 |
| Hypotension | 45 | 7.3% | 2 | 29 |
| Insomnia | 45 | 7.3% | 0 | 8 |
| Drug ineffective | 35 | 5.7% | 3 | 6 |
| Somnolence | 34 | 5.5% | 0 | 8 |
| Fatigue | 33 | 5.4% | 1 | 8 |
| Hypokalaemia | 31 | 5.0% | 6 | 25 |
| Depression | 29 | 4.7% | 2 | 2 |
| Bradycardia | 27 | 4.4% | 0 | 15 |
| Pain in extremity | 26 | 4.2% | 1 | 3 |
| Syncope | 26 | 4.2% | 2 | 13 |
| Vomiting | 25 | 4.1% | 0 | 11 |
| Treatment noncompliance | 23 | 3.7% | 0 | 1 |
| Hyperkalaemia | 19 | 3.1% | 2 | 18 |
| Depressed level of consciousness | 18 | 2.9% | 0 | 18 |
Who Reports ENALAPRIL\HYDROCHLOROTHIAZIDE Side Effects? Age & Gender Data
Gender: 54.1% female, 45.9% male. Average age: 72.4 years. Most reports from: ES. View detailed demographics →
Is ENALAPRIL\HYDROCHLOROTHIAZIDE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2003 | 1 | 1 | 0 |
| 2004 | 1 | 0 | 0 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 0 |
| 2008 | 1 | 0 | 1 |
| 2009 | 5 | 0 | 5 |
| 2011 | 5 | 0 | 1 |
| 2012 | 2 | 0 | 1 |
| 2013 | 9 | 1 | 1 |
| 2014 | 35 | 1 | 23 |
| 2015 | 26 | 1 | 18 |
| 2016 | 75 | 2 | 32 |
| 2017 | 55 | 1 | 36 |
| 2018 | 82 | 6 | 57 |
| 2019 | 49 | 0 | 28 |
| 2020 | 24 | 1 | 19 |
| 2021 | 27 | 0 | 23 |
| 2022 | 9 | 0 | 8 |
| 2023 | 30 | 0 | 24 |
| 2024 | 17 | 0 | 14 |
| 2025 | 9 | 0 | 9 |
What Is ENALAPRIL\HYDROCHLOROTHIAZIDE Used For?
| Indication | Reports |
|---|---|
| Hypertension | 281 |
| Product used for unknown indication | 212 |
| Blood pressure abnormal | 14 |
| Cardiac failure chronic | 12 |
| Intentional self-injury | 9 |
| Essential hypertension | 6 |
| Drug abuse | 5 |
ENALAPRIL\HYDROCHLOROTHIAZIDE vs Alternatives: Which Is Safer?
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENALAPRIL\LERCANIDIPINE
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENASIDENIB
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENBREL
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENCORAFENIB
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENDOXAN
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENDOXAN BAXTER
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENDOXAN , POUDRE POUR
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENFORTUMAB VEDOTIN
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENFORTUMAB VEDOTIN-EJFV
ENALAPRIL\HYDROCHLOROTHIAZIDE vs ENFORTUMAB VEDOTIN\ENFORTUMAB VEDOTIN-EJFV
Official FDA Label for ENALAPRIL\HYDROCHLOROTHIAZIDE
Official prescribing information from the FDA-approved drug label.